Dr Reddys Laboratories Ltd (RDY) stock
RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.98+0.19 (+1.28%)
Close on Nov 18, 2026Market cap $12.50BP/E 27.5Yield 0.57%
Dr Reddys Laboratories revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2026 it was ₹335.93B, up 3.2% from the year before. Over ten years it grew 8.1% a year on average. The highest annual figure on record is ₹335.93B in fiscal 2026.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | ₹335.93B | +3.2% |
| FY2025 | Mar 31, 2025 | ₹325.54B | +16.6% |
| FY2024 | Mar 31, 2024 | ₹279.16B | +13.5% |
| FY2023 | Mar 31, 2023 | ₹245.88B | +14.7% |
| FY2022 | Mar 31, 2022 | ₹214.39B | +13.0% |
| FY2021 | Mar 31, 2021 | ₹189.72B | +8.7% |
| FY2020 | Mar 31, 2020 | ₹174.60B | +13.5% |
| FY2019 | Mar 31, 2019 | ₹153.85B | +8.3% |
| FY2018 | Mar 31, 2018 | ₹142.03B | +0.9% |
| FY2017 | Mar 31, 2017 | ₹140.81B | -9.0% |
| FY2016 | Mar 31, 2016 | ₹154.71B | – |
See a number that looks wrong?